<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684853</url>
  </required_header>
  <id_info>
    <org_study_id>Pep1</org_study_id>
    <nct_id>NCT00684853</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD</brief_title>
  <official_title>Intravitreal Bevacizumab Combined With PDT (Full Fluence) Versus Bevacizumab to Treat Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the association of bevacizumab and PDT is safety
      and effective in the treatment of exudative AMD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exudative AMD is the leader of blind in people more than 60 years. The best treatment for
      this disease today are monthly injections of anti-VEGF in the vitreous cavity which increase
      the chance to get endophthalmites.

      The participants of this study will be randomized in 1:1 ration to one of the two study
      groups: single therapy of bevacizumab (3 injections in 3 months) or association of
      bevacizumab (3 injections in 3 months) and full fluence of PDT (single at the baseline). All
      bevacizumab injection will contain 1.25g of the drug and will be administrate every month for
      3 continuos months.

      After randomization, participants will return to the clinic approximately every four weeks
      for 4 months for study assessments and possible re-treatment (if is necessary). Participants
      will return to the clinic at week 20 for a final study assessment. Study assessments include:
      visual acuity, optical coherence tomography and fundus photography.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in best-corrected ETDRS visual acuity in the study eye from baseline to 4 months</measure>
    <time_frame>4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall probability of re-injection</measure>
    <time_frame>4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with reduction in retinal thickening in the center subfield (i.e., thickness &gt; 200 microns) of ³50% and of at least 50 microns from baseline</measure>
    <time_frame>4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in area of leakage, CNV and lesion by the FA and ICG</measure>
    <time_frame>4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.25 mg of bevacizumab intravitreal</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vetaporfin</intervention_name>
    <description>full fluence of vetaporfin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more or iqual 50 years old

          -  male or female

          -  Choroidal neovascularization sub or just foveal the fovea secondary to AMD
             (Predominantly Classic, Minimally Classic, and Occult lesions acceptable)

          -  Greatest linear dimension (GLD) of entire lesion &lt; 5400 µm (no reading center
             confirmation required)

          -  ETDRS best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score)

          -  Total area of lesion must &lt; 9 MPS DA

        Exclusion Criteria:

          -  pre-treatment

          -  ETDRS best corrected visual acuity better than 34 letters

          -  macular surgery history

          -  laser photocoagulation in the study eye within 30 dais

          -  eye surgery within 30 days

          -  history of no-treat glaucoma

          -  acuite uveits

          -  history of endophthalmites

          -  vitreous hemorrhage

          -  geographic atrophy or fibrosis corresponding &gt; 50% of the lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anderson G Teixeira, MD</last_name>
    <phone>323-442-6672</phone>
    <email>anderson.lbo@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta Velletri, MD</last_name>
    <phone>11-5511-5085-2041</phone>
    <email>dravelletri@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Velletri, MD</last_name>
      <phone>11-5511-5085-2041</phone>
      <email>dravelletri@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tessa Mattos, MD</last_name>
      <phone>11-5511-5085-2041</phone>
      <email>tessamattos@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2008 May;28(5):675-81. doi: 10.1097/IAE.0b013e31816b316e.</citation>
    <PMID>18463509</PMID>
  </reference>
  <reference>
    <citation>Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.</citation>
    <PMID>18462575</PMID>
  </reference>
  <reference>
    <citation>Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol. 2008 Mar-Apr;18(2):297-300.</citation>
    <PMID>18320527</PMID>
  </reference>
  <reference>
    <citation>Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol. 2008 Mar;92(3):356-60. doi: 10.1136/bjo.2007.125823.</citation>
    <PMID>18303156</PMID>
  </reference>
  <reference>
    <citation>Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007 Oct;125(10):1357-61.</citation>
    <PMID>17923543</PMID>
  </reference>
  <reference>
    <citation>Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina. 2007 Sep;27(7):891-6.</citation>
    <PMID>17891013</PMID>
  </reference>
  <reference>
    <citation>Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):17-25. Epub 2007 Aug 15.</citation>
    <PMID>17701197</PMID>
  </reference>
  <reference>
    <citation>Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, Vécsei-Marlovits P, Schmidt-Erfurth U. [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]. Ophthalmologe. 2007 Jul;104(7):588-93. German.</citation>
    <PMID>17564719</PMID>
  </reference>
  <reference>
    <citation>Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007 Jun;114(6):1179-85.</citation>
    <PMID>17544776</PMID>
  </reference>
  <reference>
    <citation>Lazić R, Gabrić N, Dekaris I, Gavrić M, Bosnar D. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol. 2007 Jan;31 Suppl 1:71-5.</citation>
    <PMID>17469756</PMID>
  </reference>
  <reference>
    <citation>Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. Epub 2007 Feb 28.</citation>
    <PMID>17333238</PMID>
  </reference>
  <reference>
    <citation>Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb;27(2):133-40.</citation>
    <PMID>17290193</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anderson Teixeira, MD</name_title>
    <organization>UNIFESP</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>PDT</keyword>
  <keyword>Avastin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Full fluence</keyword>
  <keyword>exudative</keyword>
  <keyword>CNV</keyword>
  <keyword>Drusen</keyword>
  <keyword>ARMD</keyword>
  <keyword>Vetaporfin</keyword>
  <keyword>efficacy</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

